Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2010-03-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2010.01.119PMID 20153643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation

  2009cited by this paper
• Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.

  2009cited by this paper
• First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors.

  2009cited by this paper
• Small molecule inhibitors of PKCTheta as potential antiinflammatory therapeutics.

  2009cited by this paper
• PKC inhibitors: potential in T cell-dependent immune diseases.

  2009cited by this paper
• Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.

  2009cited by this paper
• Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics

  2009cited by this paper
• 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity.

  2009cited by this paper
• Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.

  2008cited by this paper
• T-cell fate and function: PKC-theta and beyond.

  2008cited by this paper
• The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

  2008cited by this paper
• Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients.

  2006cited by this paper
• Therapeutic targets of misguided T cells in systemic lupus erythematosus.

  2005cited by this paper
• Protein kinase C and beyond

  2004cited by this paper
• Protein kinase Cδ controls self-antigen-induced B-cell tolerance

  2002cited by this paper
• Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ

  2002cited by this paper
• Protein kinase Cdelta controls self-antigen-induced B-cell tolerance.

  2002cited by this paper
• Synthesis of trans-arylvinylboronates via a palladium catalysed cross-coupling of a vinylboronate ester with aryl halides

  1994cited by this paper
• Heck versus suzuki palladium catalysed cross-coupling of a vinylboronate ester with aryl halides.

  1993cited by this paper
• NZB/NZW mice as a model of systemic lupus erythematosus.

  1966cited by this paper

• Synthesis and antioxidant assay of new nicotinonitrile analogues clubbed thiazole, pyrazole and/or pyridine ring systems

  2020cites this paper
• Synthesis, molecular modeling studies and bronchodilation properties of nicotinonitrile containing-compounds.

  2017cites this paper
• Selective and efficient synthesis of trans-arylvinylboronates and trans-hetarylvinylboronates using palladium catalyzed cross-coupling

  2017cites this paper
• Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β.

  2017cites this paper
• Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy

  2017cites this paper
• Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription.

  2015cites this paper
• The Novel PKCθ from Benchtop to Clinic

  2015cites this paper
• Protein kinase C: a regulator of cytoskeleton remodelling and T-cell migration.

  2014cites this paper
• Targeting PKCθ in skeletal muscle and muscle diseases: good or bad?

  2014cites this paper
• Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.

  2013cites this paper
• Receptor guided 3D-QSAR analysis of thieno[2,3-b]pyridine-5- carbonitrile inhibitors of protein kinase C theta (PKC-θ).

  2013cites this paper
• Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders.

  2012cites this paper
• Exploring the structure requirement for PKCθ inhibitory activity of pyridinecarbonitrile derivatives: an in silico analysis.

  2012cites this paper
• Structural Basis of Amino Pyrimidine Derivatives for Inhibitory Activity of PKC‐θ: 3D‐QSAR and Molecular Docking Studies

  2012cites this paper
• Protein Kinase Cθ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes*

  2011cites this paper
• 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.

  2011cites this paper